CN1319534C - Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method - Google Patents
Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method Download PDFInfo
- Publication number
- CN1319534C CN1319534C CNB2004100795344A CN200410079534A CN1319534C CN 1319534 C CN1319534 C CN 1319534C CN B2004100795344 A CNB2004100795344 A CN B2004100795344A CN 200410079534 A CN200410079534 A CN 200410079534A CN 1319534 C CN1319534 C CN 1319534C
- Authority
- CN
- China
- Prior art keywords
- lycopene
- linolenic acid
- ubiquinone
- acid
- gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a prescription with the functions of resisting oxidation, improving cellular respiration, resisting inflammation and improving blood circulation and a preparing method thereof. Therefore, an acceptable preparation, such as soft capsules, dripping pills, liquid agents, etc., for preventing or treating cardiovascular and cerebrovascular diseases, cancer, and hyperplasia of prostate, and delaying aging can be prepared. The present invention has the technical scheme that the preparation essentially comprises effective components of 0.5 to 40% of lycopene, 7 to 50% of coenzyme Q10, 0.3 to 70% of gamma-linolenic acid and 0.3 to 70% of alpha-linolenic acid, and auxiliary materials, the effective components of the lycopene, the coenzyme Q10, the gamma-linolenic acid, the alpha-linolenic acid, etc. are prepared into the prescription according to a certain proportion, and the one-time used dose in the prepared finished product contains 2.5 to 20 mg of lycopene, 3.5 to 25 mg of coenzyme Q 10, 1.5 to 150 mg of gamma-linolenic acid and 1.5 to 150 mg of alpha-linolenic acid. Except for linoleic acid, other solvent substrates are composed of one kind or several kinds of oleic acid, linoleic acid, etc. of single and/or multiple unsaturated fatty acid, etc. of edible plant oil or medicinal oil. According to requirements, perfumery agents (such as cinnamon oil, etc.) can be added into physic liquor. The product of the present invention can be prepared into the acceptable preparations of soft capsules, dripping pills, liquid agents, etc.
Description
Technical field: the present invention relates to a kind ofly have antioxidation, improve Cellular respiration, antiinflammatory and improve the prescription of blood circulation function, thereby can prepare acceptable preparations such as the soft capsule that is used to prevent or treat diseases such as cardiovascular and cerebrovascular disease, cancer, prostatic hyperplasia, slow down aging, drop pill, liquid agent and preparation method thereof.
Background technology: lycopene (Lycopene) is a kind of of carotenoid, is present in the many plants of nature as a kind of natural pigment, takes on a red color, and gains the name because of being found in Fructus Lycopersici esculenti the earliest.From nineteen ninety-five so far, hundreds of pieces of documents relate to the functional study and the clinical efficacy of lycopene, the physiological function that relates to is more, has affirmed fully the effect of the anti-oxidation function of lycopene and prevention of prostatic hyperplasia, carcinoma of prostate.Therefore lycopene is applied in the health food, a lot of abroad, mainly be to be used for slow down aging, carcinoma of prostate etc.The patent of relevant lycopene is a lot, as " goods (Russia) that contain lycopene; the prescription that contains beta-carotene, lycopene and phylloxanthin is used for food, medicine and cosmetics " (moral), " Synergistic blend that contains natural products such as lycopene " (English), " food supplement that contains lycopene, Radix Oenotherae erythrosepalae oil and Semen Cucurbitae oil " (method), " food supplement that contains lycopene, polyunsaturated fatty acid and antioxidant " (method) etc.The lycopene bioavailability is higher in oils and fats.Fat is to influence lycopene in one of key factor of intestinal absorption.
Ubiquinone
10(can abbreviate Co Q as
10. if when comprising homologue, then abbreviate Co Q as, the IUPAC-IUB-CBN name is called Ubiquinone-10, and nomenclature of drug is Ubibecarenone), be to obtain at first by separating in the myocardial mitochondria of cattle.Being present in the mitochondrial inner membrance of many senior animals and plants based on the mankind, is the neccessary composition of forming respiratory chain.In the time of 20 years old, the body coenzyme Q
10Reach peak, reduced gradually later in 20 years old.Ubiquinone in the market
10There are defectives such as bioavailability difference is big, individual variation is big in preparation, seeks new ubiquinone
10Preparation technique and/or prescription, to improve bioavailability, the influence that reduces individual variation is the important topic that faces in the current exploitation.
Gamma-Linolenic acid, English name γ-Linolenic acid or Gamma-Linolenic acid are called for short GLA, and formal name used at school is all-cis formula-6,9,12-jeceric acid.Belong to n-6 or ω-6 type fatty acids (6-Fatty acids).Gamma-Linolenic acid is a kind of polyunsaturated fatty acid, and it is low, water insoluble to have a fusing point, is soluble in the characteristic of non-polar solven.Can think that generally gamma-Linolenic acid is the fatty acid of needed by human, it also is the synthetic precursor of human body to the significant prostaglandin of life, body disease-resistant anti-aging there is significant good effect, gamma-Linolenic acid can be nonesterified in human body form exist or participate in the constituent of cholesterol, triglyceride and phospholipid with the form of esterification, be biomembranous important component.
Gamma-Linolenic acid application abroad, the health product that contain gamma-Linolenic acid can buy in developed country most wholefood shop, also are the health product (medicine) that health care and prevention doctor take much count of always and recommend.Be subjected to the welcome of consumer in earth polars such as America and Europes.Main as premenstrual syndrome, erythra, antiinflammatory, cardiovascular and cerebrovascular disease, anticancer etc.
Alpha-linolenic acid, English name α-Linolenic acid, formal name used at school are all-cis formula-9,12,15-jeceric acid.Alpha-linolenic acid is a kind of polyunsaturated fatty acid, and it is low, water insoluble to have a fusing point, is soluble in the characteristic of non-polar solven.Put easily oxidation in the air, hard rete is polymerized.Belong to n-3 or ω-3 type fatty acids (3-Fatty acids).Can think that generally alpha-linolenic acid is the fatty acid of needed by human.
The seventies in last century, U.S. scientist noticed an interesting phenomenon, the Eskimos who moves in Alaska a large amount of fat of all ingesting every day, but the sickness rate of their heart disease and cancer is all very low.Analyze to disclose in the fat that reason is that they take in and contain fine n-3 or ω-3 type fatty acid, U.S.'s cardiopulmonary institute (the National Heart Lung Institute) confirms that (1 gram) n-3 type fatty acid of picked-up every day trace can make the sickness rate of cardiovascular disease lower 40% more than.
Aspect cardiovascular health, alpha-linolenic acid is a kind of blood thinners, can prevent blood clot to form, and four mechanisms of the U.S. unite the tests confirmation of being done 15000, and being rich in n-3 type fatty acid has pretty good effect to cardiovascular health.The pathologist shows 40 tool postmortems, n-3 type total fatty acid content in the abdominal tissues and coronary atherosclerosis and the degree of narrowing that causes has direct relation.The animal experiment that Australian Union's science and industrial research association (Australia ' s Commonwealth Scientific and IndustrialResearch Organazation) are carried out shows that the animal of feeding n-3 type fatty acid is difficult for suffering from the disease of arrhythmia.Holland has a long-term research to show, the apoplectic seizure rate medicine of taking in a certain amount of n-3 type fatty acid every day obviously reduces.Common lycopene and ubiquinone
10Bioavailability is low, is difficult to play stable curative effect, more is difficult to arrive prostate.Lycopene and ubiquinone
10Bioavailability in oils and fats is higher, and fat is to influence lycopene and ubiquinone
10In one of key factor of intestinal absorption.
Summary of the invention: the invention reside in provides a kind of lycopene and ubiquinone
10With linolenic acid compound after, biological activity is collaborative mutually to be improved, bioavailability also improves greatly, especially helps arriving the inaccessible prostata tissue of general bioactive substance, thereby helps bringing into play better lycopene and ubiquinone
10Therapeutic effect (as to therapeutical effect of prostatic hyperplasia etc.) contain lycopene and ubiquinone
10Preparation and preparation method thereof.
5, technical scheme of the present invention is: said preparation product essence contains lycopene, ubiquinone
10, gamma-Linolenic acid, alpha-linolenic acid functional component, its surplus is an adjuvant.With lycopene, ubiquinone
10, effective ingredient such as gamma-Linolenic acid, alpha-linolenic acid compositing formula by a certain percentage, as follows: lycopene 0.5%-40%
Ubiquinone
100.7%-50%
Gamma-Linolenic acid 0.3%-70%
Alpha-linolenic acid 0.3%-70%
Contain lycopene 2.5-20mg, ubiquinone in the each dosage that uses of the finished product of making
103.5-25mg, gamma-Linolenic acid 1.5-150mg, alpha-linolenic acid 1.5-150mg, surplus is a pharmaceutic adjuvant.Except that linolenic acid, other solvent substrates are one or more compositions in plant edible foods such as lists such as oleic acid, linoleic acid and/or polyunsaturated fatty acid or the medicinal oil.As required, can add deodorant tune (as the Cortex Cinnamomi wet goods) in the medicinal liquid.Product of the present invention can make soft capsule, drop pill, liquid agent etc. can accept preparation.
The lycopene ubiquinone that the invention provides the active height of a kind of oral artifact, absorb better, stability of drug products is good, easy to use
10The linolenic acid joint product.
The drug effect of product of the present invention:
1, product stability: the various product stabilities of making are good, and the linolenic acid oxygenation efficiency is low;
2, effect such as antioxidation, removing interior free yl;
3, improve senile symptom;
4, improve symptoms such as frequent micturition, dysuria;
5, improve bioavailability:
The specific embodiment: for of the present invention may the combination clearly is described, provide above embodiment, but never be in order to limit the present invention, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Embodiment 1, compound recipe lycopene ubiquinone
10Soft capsule
Prescription (1000):
Lycopene 5g
Ubiquinone
107g
Alpha-linolenic acid (containing alpha-linolenic acid 24%): 160g
Gamma-Linolenic acid (containing gamma-Linolenic acid 20%) 330g
Technology:
Under nitrogen protection, alpha-linolenic acid and gamma-Linolenic acid mixing with formula ratio add lycopene and ubiquinone
10, fully stir, dissolve, filter, outgas, deliver in the jar of filling machine top, stand-by; Be ready to the gelatin solution that the rubber in the soft capsule filling machine top insulation gelatin jar is used simultaneously, stand-by; Under 300,000 grades, 21 ℃～25 ℃, the condition of RH%:39～41%, start rotating mould press pelleting, the soft capsule of making is cleaned, 28+2 ℃ dry 19～27 hours down, packing, packing promptly get compound recipe lycopene ubiquinone
101000 of the red soft capsule finished products of soft capsule 500mg (intragranular is tolerant heavy).
Embodiment 2, compound recipe lycopene ubiquinone
10Soft capsule
Prescription (100,000):
Lycopene 0.6kg
Ubiquinone
101kg
Alpha-linolenic acid (containing alpha-linolenic acid 83%): 9kg
Gamma-Linolenic acid (containing gamma-Linolenic acid 7%) 40kg:
Technology:
With embodiment 1 (summary).100,000 of the red soft capsule finished products of 500mg content.
Embodiment 3, compound recipe lycopene ubiquinone
10Soft capsule
Prescription (1000):
Lycopene 20g
Ubiquinone
108g
Alpha-linolenic acid (containing alpha-linolenic acid 12.3%): 140g
Gamma-Linolenic acid (containing gamma-Linolenic acid 82.8%) 335g:
Technology:
With embodiment 1 (summary).1000 of every red soft capsule finished products that contains the 500mg content.
Embodiment 4: compound recipe lycopene ubiquinone
10Drop pill
Prescription: (1000):
Lycopene 5g
Ubiquinone
1025g
Alpha-linolenic acid (containing alpha-linolenic acid 77.1%): 10g
Gamma-Linolenic acid (containing gamma-Linolenic acid 64.6%) 10g:
PEG-6000 700g
Technology:
PEG-6000 is placed stainless-steel pan, is heated to 90-100 ℃ in oil bath, treat whole fusions after, add mixed liquor and the lycopene and the ubiquinone of α acid and gamma-linolenic
10, stir, be transferred in the liquid containing bottle, airtight and insulation is regulated the dropping liquid proportional valve at 80-90 ℃, from top to bottom, splashes in 10-15 ℃ the liquid Paraffin, puts in the Calx cylinder dry.Get compound recipe lycopene ubiquinone
10Drop pill, every red drop pill finished product that contains effective composition 50mg.(taking 10 balls) at every turn
Embodiment 5: compound recipe lycopene ubiquinone
10Drop pill
Prescription: (1000):
Lycopene 10g
Ubiquinone
1010g
Alpha-linolenic acid (containing alpha-linolenic acid 16.1%): 40g
Gamma-Linolenic acid (containing gamma-Linolenic acid 8.6%) 60g:
PEG-6000 800g
Technology
With embodiment 4 (summary).Get red drop pill finished product.(taking 10 balls) at every turn
Embodiment 6, compound recipe lycopene ubiquinone
10Fat emulsion oral liquid
Prescription: (1000):
Lycopene 5g
Ubiquinone
1025g
Alpha-linolenic acid (containing alpha-linolenic acid 8.3%) 1800g
Gamma-Linolenic acid (containing gamma-Linolenic acid 4.7%) 1800g
Glycerol 650g
Soybean phospholipid 380g
Preparation technology: under 100 grades condition, under nitrogen protection, soybean phospholipid is added no saline 10000ml, add α acid and gamma-linolenic fluid, lycopene, ubiquinone again
10, be stirred to moltenly, add glycerol, add no saline to 25000ml.In 70-80 ℃ with organizing beating crusher to make thick breast.Thick breast is cooled to rapidly below 20 ℃, and the high pressure dispersing emulsification machine emulsifying of two step of reuse promptly gets finely divided submicron emulsion (fat milk).Send into racking machine, by every bottle of 10ml packing, Zha Gai, packing, check, qualified, finished product.Can make the compound fatty milk oral liquid finished product of the specification of 2500 10ml.
Product study of pharmacy and effect:
One, the stability of product
The lucifuge keeping at room temperature of 1,2,3,4,5,6 six samples of embodiment was placed 1,2,3,6,12 month, checked that on time it is constant substantially that every sample gets outward appearance, and effective ingredient does not change through check yet.Peroxide value is constant.Therefore, think that tentatively various products and various prescription all can reach the shelf-life about 1 year.
The stability test result:
| Sample | Sample size, discriminating | ||||
| January | February | March | June | December | |
| Example 1 example 2 examples 3 examples 4 examples 5 examples 6 | Qualified qualified | Qualified qualified | Qualified qualified | Qualified qualified | Qualified qualified |
The result shows the sample of this invention preparation, and through the preliminarily stabilised investigation, product quality is basicly stable, can reach more than 1 year.
Two, effects such as defying age, antioxidation, removing interior free yl
(1) blood fat reducing
Material
1. animal: SD rat, body weight 180-230g, the quality certification number " the moving pipe of cloud B04 ".
2. medicine and reagent:
Compound recipe lycopene ubiquinone
10The sample code name FLQ that soft capsule embodiment 1 makes
Cholesterol: Shanghai chemical reagent packing, lot number: 950517
Cholate: east, Suzhou medical biochemical product factory produces lot number: 960101
The propylthiouracil sheet: bridge pharmaceutical factory in Guangzhou produces, lot number: 900523
Adeps Sus domestica: commercially available
Fenofibrate: Taixing, Jiangsu pharmaceutical factory produces, lot number: 960816
3. instrument: Mooarch1000 type full automatic biochemical apparatus (U.S.'s product)
Method
1. high fat emulsifying agent preparation
With cholesterol, propylthiouracil sheet pulverize.Be mixed with lipomul (W/V) by 10% cholesterol, 2% cholate, 1% propylthiouracil, 20% Adeps Sus domestica amount with distilled water.Refrigerator is preserved, and the time spent places in the hot bath and melts.
2. compound recipe lycopene ubiquinone
10Soft capsule is to the influence of rat hyperlipidemia model serum lipids
With 40 of above-mentioned SD rats, be divided into the heavy dose of group of (1) normal control group (2) model control group (3) FLQ small dose group (4) FLQ at random, every group of 10 rats, male and female half and half.Grouping back animal every morning (1) group ig give distilled water, (2) (3)
(4) group ig gives isopyknic high lipoprotein emulsion; Hereinafter ig145mg/kg, 290mg/kg are respectively organized in (3) (4), and (1) (2) group is given distilled water, continuously 20d.After the last administration, animal fasting 16h, rat eye socket venous plexus is got blood, and separation of serum is with enzymatic assays serum cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL-C), low density lipoprotein, LDL (LDL-C), ApoA (APOA), apolipoprotein B (APOB).The results are shown in Table.
The result
By table as seen, the FLQ high dose group can significantly reduce the TC (P＜0.05) in the hyperlipidemia model rat serum, and low agent group also has reduction trend; Two groups of TG are reduced significantly (P＜0.01); HDL-C, LDL-C, APOA, APOB are not made significant difference.
FLQ
| Group | TC (mmol/L) | TG (mmol/L) | HDL-C (mmol/L) | LDL-C (mmol/L) | APOA (mmol/L) | APOB (mmol/L) |
| The normal control group | 1.37±1.02 | 0.92±0.29 | 0.99±0.25 | 0.18±0.18 | 0.379±0.010 | 0.052±0.042 |
| Model control group | 2.67±0.33 | 0.85±0.22 | 1.12±0.38 | 1.10±0.19 | 0.373±0.011 | 0.050±0.012 |
| Fenofibrate | 2.62±0.25 | 0.74±0.13 | 1.14±0.21 | 1.30±0.31 | 0.384±0.016 | 0.049±0.017 |
| Model+high dose group | 2.30±0.26 * | 0.51±0.23 ** | 1.09±0.23 | 0.92±0.29 | 0.381±0.018 | 0.057±0.005 |
| Model+low dose group | 2.45±0.28 | 0.54±0.20 ** | 1.04±0.29 | 1.23±0.22 | 0.363±0.005 | 0.051±0.005 |
Model control group and normal control group compare: △ P＜0.05 △ △ P＜0.01
Administration group and model control group compare:
*P＜0.05
*P＜0.01
(2) FLQ is to the nootropic effect research of aged animal model
1 material
1.1 laboratory animal ICR mice, body weight 20 ± 2g, male and female half and half are provided by Yunnan Province natural drug pharmacology key lab, and the animal quality certification is numbered: No. the 00205th, the real moving card in Yunnan.
1.1.2 medicine and reagent
1.1.2.1 the sample that test sample embodiment 2 makes (code name FLQ).Face the time spent, be mixed with 5%, 10% and 20% suspension with 1% carmethose.
1.1.2.2 reference substance brain recovering capsule faces the time spent, the carboxylic first fiber sodium with 1% is mixed with 5% suspension.
1.2 experimental technique and result
Earlier mice is divided into blank group and aging model group.Aging model group mice retrobulbar injection every day D-galactose 0.12mg/g, January [1] continuously.Divide some groups after the mice moulding as required again.Mice does following grouping at random during experiment: (1) blank group (not moulding of animal), irritate stomach N.S.(2) moulding matched group (animal-shaped) is irritated stomach N.S.(3) positive drug control group, animal-shaped, filling stomach brain recovering capsule solution (0.5g/kg is clinical two times of adult's dosage).(4)-(6) group is the basic, normal, high dosage group of FLQ, irritates the FLQ solution (dosage is respectively clinical 2,5 and 10 times adult's dosage) of stomach 5%, 10% and 20% respectively.Each is organized the mouse stomach volume and is 10ml/kg, once a day, and continuous two weeks.After the last administration, make following index determining.
1.2.1FLQ the influence that the learning and memory of aging model mice is kept
1.2.1.1 step down test is imitated literature method
[2], earlier mice was put into diving tower reaction chamber endoadaptation environment 3 minutes, pass to the 36V alternating current to the copper grid at the bottom of the reaction chamber then, after animal is shocked by electricity, tend to skip to platform, to keep away noxious stimulation.Because platform is narrow, inconvenience stops, and forces it to skip to the copper grid once more or repeatedly, but rebound platform promptly again after being shocked by electricity so trained 5 minutes, writes down the number of times that every Mus is shocked by electricity, with this school grade as this Mus.Recast test after 24 hours.During test, earlier mice is placed on the platform, time (incubation period) and the 3 minutes endogenous cause of ill that the record mice jumps off platform is for the first time jumped off platform and the number of times (being errors number) that shocked by electricity, with this index of keeping as memory.The results are shown in Table 1.
Table 1 FLQ is to influence (diving tower method) x ± SD of aging model learning and memory of little mouse, n=20
| Group | Dosage (g/kg.d) | School grade | Memory is kept | |
| The 5min errors number | Diving tower incubation period (second) | The 5min errors number | ||
| Dosage Q high dose among the blank assembly molding contrast positive drug contrast F low dosage L | N.S 10ml N.S 10ml 0.5 0.5 1.0 2.0 | 3.2±1.2** 4.8±1.3 3.7±1.2** 3.6±1.4** 3.8±1.3** 3.5±1.0** | 82.6±14.6** 50.4±12.2 63.2±15.5** △△ 70.1±15.6** 78.7±17.6** 85.0±19.0** | 3.9±1.5** 8.9±2.6 5.5±1.7** △△ 5.3±1.7** △△ 4.3±1.6** 5.2±2.1** △ |
Annotate: compare with the moulding matched group: *: P＜0.05 * *: P＜0.01.
Compare with the blank group:
△: P＜0.05;
△ △: P＜0.01
Above result shows, FLQ significant prolongation mice diving tower incubation period, obviously reduces the errors number (P＜0.01) of diving tower simultaneously.
1.2.1.2 it is a collection of that square type maze test is got the qualified mice of moulding, divides into groups and administration (or N.S) by above-mentioned test.Be administered to the 11st day, fasting was got the food training as the labyrinth after 12 hours.Mice is put into the starting area, arrives the target area through the rectangle labyrinth.Go to the wrong way in the way, help its correction.Reach its feed of target area relief 5 minutes.So practise 10 times every day, continuous three days.The 4th day (being the fortnight of administration) formal experiment.Each group is chosen 20 of the consistent mices of motility, and the record mice arrives the time of target area and the number of times of going to the wrong way [3] midway from the starting area.Doing the merging of twice, two secondary data continuously averages as the school grade of mice.Animal continues administration, repeats above-mentioned test after the week, and what the gained data were promptly represented to remember keeps, and the results are shown in Table 2:
Table 2 FLQ is to improvement effect (maze method) x ± SD n=20 of aging model learning and memory of little mouse
| Group | Dosage | Learning period arrives the target area | The arrival target area is kept in memory | |||
| (g/kg.d) | Required time (second) | Errors number | Required time (second) | Errors number | ||
| The contrast of blank assembly molding matched group positive drug | N.S 10ml N.S 10ml 0.5 | 31.1±6.3** 46.8±10.2 38.8±7.0* | 3.5±1.2** 4.9±1.6 3.0±1.1** | 39.9± 9.8** 52.5±9.8 39.1± 5.2** | 3.9±1.5** 5.9±1.4 3.4±0.8** | |
| F L Q | Dosage high dose in the low dosage | 0.5 1.0 2.0 | 40.0±6.2* △△ 37.6±7.1** △△ 34.2±5.2** | 3.1±0.8** 3.1±0.8** 2.5±1.1** △ | 43.4± 6.8** 40.3± 6.6** 37.7± 4.6** | 3.7±1.2** 3.8±0.8** 2.9±0.8** △ |
Annotate: compare with the moulding matched group: *: P＜0.05 * *: P＜0.01.
Compare with the blank group:
△: P＜0.05;
△ △: P＜0.01
Above result shows that FLQ obviously improves the school grade that the aging model mice walks the labyrinth, reduces the memory phase of keeping and walks the errors number that the labyrinth takes place, and promptly strengthens the maintenance effect of mice to memory.
1.2.2FLQ it is a collection of that mice is got in the influence of monoamine neurotransmitters in aging model mice serum MDA and SOD content and the cerebral tissue, grouping and dosage and method are tested with above-mentioned 1.2.1.But administration (or N.S) time is two courses of treatment (28 days), gets blood and gets the full brain of mice from femoral artery in one hour after the last administration.Measure the content of respectively organizing malonaldehyde in the mice serum (MDA) and superoxide dismutase (SOD) respectively by the described method of testing cassete that Nanjing is built up bio-engineering research and provided
[4]Measure the content of monoamine neurotransmitter in the mouse brain tissue with fluorescence spectrophotometry.Operational approach and result are as follows:
The assay of serum malonaldehyde (MDA), the according to the form below operation
| Standard pipe | The blank pipe of standard | Measure pipe | Measure blank pipe | |
| 10nmol/m standard substance (ml) | 0.1 | |||
| Dehydrated alcohol (ml) | 0.1 | |||
| Specimen (ml) | 0.1 | 0.1 | ||
| Reagent one (ml) | 0.1 | 0.1 | 0.1 | 0.1 |
Mixing (shaking several test tube racks down)
| Reagent two (ml) | 3 | 3 | 3 | 3 |
| Reagent three (ml) | 1 | 1 | 1 | |
| 50% glacial acetic acid (ml) | 1 |
Vortex vortex mixer mixing, the test tube mouth is tightened with antistaling film, sting an aperture,, take out back flowing water cooling in 95 ℃ of water-baths 40 minutes, centrifugal then (4000rpm) 10 minutes, get supernatant, the 1cm of 532nm place optical path, distilled water zeroing colorimetric, survey and respectively manage the absorbance value, press the content of MDA in the column count serum again:
The vitality test of serum superoxide dismutases (SOD), the according to the form below operation
| Reagent | Measure pipe | Control tube |
| No. 1 reagent (ml) | 1.00 | 1.0 |
| Sample (ml) | 0.03 | |
| Distilled water (ml) | 0.50 | 0.5+0.03 |
| No. 2 reagent (ml) | 0.1 | 0.1 |
| No. 3 reagent (ml) | 0.1 | 0.1 |
| No. 4 reagent (ml) | 0.1 | 0.1 |
With the abundant mixing of vortex vortex mixer, put 37 ℃ of waters bath with thermostatic control 40 minutes
| Developer (ml) | 2 | 2 |
Mixing is poured into after 10 minutes in the 1cm optical path cuvette, and the distilled water zeroing in wavelength 550nm place colorimetric, is calculated as follows SOD vigor (nu/ml)
The results are shown in Table 3:
Table 3 FLQ is to the x ± SD that influences of mice plasma MDA and SOD
| Group | Dosage (g/kg.d) | n | MDA(nmol/ml) | SOD(nu/ml) | ||
| Blank | N.S 10ml | 20 | 7.2±0.8** | 87.8±21.0** | ||
| The model contrast | N.S 10ml | 20 | 10.5±1.0 | 37.5±15.0 | ||
| Positive drug is right | 0.5 | 20 | 7.9±0.8** | 50.8±11.5** △△ | ||
| F L Q | Low dosage | 0.5 | 20 | 7.6±0.9** | 55.1±10.4** △△ | |
| Middle dosage | 1.0 | 20 | 7.4±0.8** | 57.6±13.2** △△ | ||
| High dose | 2.0 | 20 | 7.2±1.0** | 68.0±12.6** △△ | ||
Annotate: compare with the moulding matched group: *: P＜0.05 * *: P＜0.01.
Compare with the blank group:
△: P＜0.05;
△ △: P＜0.01
Above result shows that FLQ can obviously reduce the activity of blood plasma lipide peroxidating content of mda and raising blood plasma superoxide dismutase (SOD).
Three, improve senile symptom
Have easily anoxybiotic old people volunteer 10 examples more than 75 years old of senile plaque, movable back, oral product of the present invention (the red soft capsules of embodiment 2 gained), after continuous 5 months, on inspection, experimenter's hemorheology improves, and the blood fat peroxide value descends, senile plaque alleviates or disappears, hypoxia-bearing capability improves, and the phenomenon of breathing after motion or the activity obviously alleviates, and mental status obviously improves.
Four, improve prostatic hyperplasia symptoms such as frequent micturition, dysuria
Be diagnosed as the voluntary oral product of the present invention of 25 examples of old people more than 70 years old (the red soft capsule of embodiment 2 gained) of prostatic hyperplasia through hospital, take obviously improvement of prostatic hyperplasia symptoms appearance such as frequent micturition, dysuria after 2 months continuously, do not add ubiquinone than taking
10The short treating period instant effect.
Five, improve bioavailability: compare lycopene and ubiquinone in this product with ordinary preparation
10Bioavailability can improve lycopene and ubiquinone in 30-55%, the blood plasma
10Contents level improves more than 2 times.
Claims (6)
1, a kind of lycopene and ubiquinone of containing
10And the formulation products that is used for the prophylactic treatment prostatic hyperplasia is characterized in that said preparation product essence contains lycopene, ubiquinone
10, gamma-Linolenic acid, alpha-linolenic acid functional component, each functional component proportion of composing is in the product:
Lycopene 0.5%-40%
Ubiquinone
100.7%50%
Gamma-Linolenic acid 0.3%-70%
Alpha-linolenic acid 0.3%-70%
Its surplus is a pharmaceutic adjuvant.
2, lycopene and the ubiquinone of containing according to claim 1
10And the formulation products that is used for the prophylactic treatment prostatic hyperplasia is characterized in that containing lycopene 2.5-20mg, ubiquinone in the each dosage that uses of the product of making
103.5-25mg, gamma-Linolenic acid 1.5-150mg, alpha-linolenic acid 1.5-150mg, surplus is a pharmaceutic adjuvant.
3, lycopene and the ubiquinone of containing according to claim 1 and 2
10And the formulation products that is used for the prophylactic treatment prostatic hyperplasia is characterized in that solvent substrate is one or more compositions in list and/or polyunsaturated fatty acid plant edible food or the medicinal oil.
4, lycopene and the ubiquinone of containing according to claim 3
10And the formulation products that is used for the prophylactic treatment prostatic hyperplasia is characterized in that solvent substrate is oleic acid, linoleic acid.
5, lycopene and the ubiquinone of containing according to claim 1 and 2
10And the formulation products that is used for the prophylactic treatment prostatic hyperplasia is characterized in that adding in the medicinal liquid Oleum Cinnamomi deodorant tune.
6, lycopene and the ubiquinone of containing according to claim 1 and 2
10And the formulation products that is used for the prophylactic treatment prostatic hyperplasia is characterized in that product makes soft capsule, drop pill, liquid agent preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100795344A CN1319534C (en) | 2004-10-28 | 2004-10-28 | Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100795344A CN1319534C (en) | 2004-10-28 | 2004-10-28 | Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634075A CN1634075A (en) | 2005-07-06 |
| CN1319534C true CN1319534C (en) | 2007-06-06 |
Family
ID=34847115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100795344A Expired - Fee Related CN1319534C (en) | 2004-10-28 | 2004-10-28 | Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1319534C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007119407A (en) * | 2005-10-28 | 2007-05-17 | Av Ovo:Kk | Coenzyme q10-containing composition, and food or preparation containing the composition |
| ES2285923B1 (en) * | 2005-12-14 | 2008-10-16 | Dieta Mediterranea Aceites Y Vinagres, S.A. | PRODUCT FOR USE IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES, CANCER AND CHRONIC INFLAMMATORY DISEASES. |
| ITMI20061874A1 (en) * | 2006-09-29 | 2006-12-29 | Rosario Ammirante | COMPOSITION FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGICAL STATES OF THE CENTRAL AND PARTICULAR NERVOUS SYSTEM IN PARKINSON'S DISEASE |
| CN103083501A (en) * | 2012-11-13 | 2013-05-08 | 江苏艾兰得营养品有限公司 | Soft capsule preparation for preventing and treating diseases of old people |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54129132A (en) * | 1978-03-29 | 1979-10-06 | Eisai Co Ltd | Remedy and prophylactic for prostatomegaly |
| CN1489997A (en) * | 2002-10-15 | 2004-04-21 | 北京吉尔兹技贸有限公司 | Anticancer nutritive Chinese medicine |
| CN1522143A (en) * | 2001-05-30 | 2004-08-18 | Coenzyme q and eicosapentaenoic acid (epa) |
-
2004
- 2004-10-28 CN CNB2004100795344A patent/CN1319534C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54129132A (en) * | 1978-03-29 | 1979-10-06 | Eisai Co Ltd | Remedy and prophylactic for prostatomegaly |
| CN1522143A (en) * | 2001-05-30 | 2004-08-18 | Coenzyme q and eicosapentaenoic acid (epa) | |
| CN1489997A (en) * | 2002-10-15 | 2004-04-21 | 北京吉尔兹技贸有限公司 | Anticancer nutritive Chinese medicine |
Non-Patent Citations (4)
| Title |
|---|
| A-亚摩酸的研究进展 李英霞等，中草药，第32卷第7期 2001 * |
| A-亚摩酸的研究进展 李英霞等，中草药，第32卷第7期 2001;Y-亚摩酸的保健作用 董杰明等，卫生研究，第32卷第3期 2003;番茄红素研究进展及应用前景 韩美清等，山地农业生物学报，第22卷第5期 2003 * |
| Y-亚摩酸的保健作用 董杰明等，卫生研究，第32卷第3期 2003 * |
| 番茄红素研究进展及应用前景 韩美清等，山地农业生物学报，第22卷第5期 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634075A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS58189110A (en) | Nutritious lipid composition | |
| KR20060127865A (en) | Fat composition | |
| CN102283386A (en) | Composite camellia oil health care product with function of reducing blood fat and preparation method thereof | |
| CN105079009B (en) | Prevention and/or the composition for the treatment of cardiovascular and cerebrovascular disease | |
| CN1965806A (en) | Fat emulsion injection liquid containing soybean oil, medium chain triglyceride, olive oil and fish oil and method for preparing the same | |
| CN112399847B (en) | Vitamin K2 microcapsule, preparation method thereof and application thereof in preparing medicament for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN107441217B (en) | Oral emulsion rich in alpha-linolenic acid and preparation method thereof | |
| CN109893513B (en) | Composite haematococcus pluvialis astaxanthin self-emulsifying soft capsule and preparation method and application thereof | |
| CN1319534C (en) | Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method | |
| JPH0542411B2 (en) | ||
| CN102106534A (en) | Composition for assisting in lowering blood fat and preparation method thereof | |
| CN1539462A (en) | Health product of compound propolis and preparing method | |
| CN1843406A (en) | Blood fat-reducing medicine and its preparation method | |
| CN1108111C (en) | Hypolipemic rice-flour noodles and its preparing process | |
| JPS61118323A (en) | Composition having improving action on serum lipid | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| CN109699887A (en) | A kind of peony seed oil blood fat reducing soft capsule and preparation method thereof | |
| JP7245399B2 (en) | Method for increasing blood decanoic acid concentration, agent for increasing blood decanoic acid concentration, pharmaceutical composition, food composition | |
| CN100544711C (en) | A kind of formulation product of prevention of prostatic hyperplasia | |
| CN1568958B (en) | Unsaturated fatty acid formula products with high content of alpha and gamma linolenic acid and preparation method threreof | |
| CN1634015A (en) | Confected product containing lutein and/or carotene linolenic acid, and its preparation method | |
| CN1899389A (en) | Medicinal composition for preventing and treating female senile diseases and method for preparing said preparation | |
| CN117379555A (en) | Safflower seed oil matrix and application thereof | |
| CN206596643U (en) | Vegetarian diet capsule structure containing unrighted acid | |
| CN1282474C (en) | Medicine for treating hyper lipidemia and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070606 Termination date: 20091130 |